Display options
Cite
Simmonds HA, Bowyer A. Purine and pyrimidine excretion in psoriasis: a comparison with healthy controls during allopurinol therapy. Br J Clin Pharmacol. 1974;1(2):107-11doi: 10.1111/j.1365-2125.1974.tb00218.x.
Simmonds, H. A., & Bowyer, A. (1974). Purine and pyrimidine excretion in psoriasis: a comparison with healthy controls during allopurinol therapy. British journal of clinical pharmacology, 1(2), 107-11. https://doi.org/10.1111/j.1365-2125.1974.tb00218.x
Simmonds, H A, and Bowyer, A. "Purine and pyrimidine excretion in psoriasis: a comparison with healthy controls during allopurinol therapy." British journal of clinical pharmacology vol. 1,2 (1974): 107-11. doi: https://doi.org/10.1111/j.1365-2125.1974.tb00218.x
Simmonds HA, Bowyer A. Purine and pyrimidine excretion in psoriasis: a comparison with healthy controls during allopurinol therapy. Br J Clin Pharmacol. 1974 Apr;1(2):107-11. doi: 10.1111/j.1365-2125.1974.tb00218.x. PMID: 22454896; PMCID: PMC1402458.
Copy Download .nbib Format: NLM
Share it on

Br J Clin Pharmacol. 1974 Apr;1(2):107-11. doi: 10.1111/j.1365-2125.1974.tb00218.x.

Purine and pyrimidine excretion in psoriasis: a comparison with healthy controls during allopurinol therapy.

British journal of clinical pharmacology

H A Simmonds, A Bowyer

Affiliations

  1. Department of Medicine, Guy's Hospital Medical School, London Bridge.

PMID: 22454896 PMCID: PMC1402458 DOI: 10.1111/j.1365-2125.1974.tb00218.x

Abstract

1 Urinary purine excretion has been investigated in two healthy controls and two patients with psoriasis, one a hyperuricaemic, one a normouricaemic. No difference was detected between the patients and controls. Therapy with allopurinol effectively lowered blood and urinary uric acid levels and produced a deficit in total urinary oxypurine excretion in both controls and patients with psoriasis. The concomitant increase in xanthine excretion was greater than the increase in hypoxanthine excretion and xanthine/hypoxanthine ratios (average 0.70 and 1.0 prior to therapy) were increased by allopurinol to an average of 3.0 and 3.8 respectively in the two groups. Allopurinol also reduced the excretion of 8-hydroxy-7-methyl guanine but no effect on the excretion levels of other minor purine bases was noted. 2 Allopurinol was metabolized similarly by both patients and controls, 84% of the administered allopurinol being accounted for as urinary metabolites. 74% of the drug in the urine was excreted as oxipurinol, 26% as unchanged allopurinol plus allopurinol riboside, the remainder being oxipurinol riboside. 3 Pseudouridine excretion in 25 healthy controls was 86.5 ± 17.8 mg/24 hours. Pseudouridine excretion was not excessive in the patients with psoriasis and was not altered by allopurinol therapy. 4 No abnormality or difference in purine or pyrimidine excretion in either patient was detected prior to or during therapy which could be related to the epidermal lesion.

References

  1. J Invest Dermatol. 1961 Feb;36:105-7 - PubMed
  2. Science. 1970 May 15;168(3933):861-2 - PubMed
  3. J Lab Clin Med. 1962 May;59:852-8 - PubMed
  4. J Invest Dermatol. 1961 Aug;37:125-33 - PubMed
  5. J Invest Dermatol. 1958 Nov;31(5):269-71 - PubMed
  6. Ann Rheum Dis. 1966 Nov;25(6 Suppl):657-9 - PubMed
  7. Ann Rheum Dis. 1966 Nov;25(6 Suppl):634-42 - PubMed
  8. Biochem J. 1954 Nov;58(3):426-37 - PubMed
  9. Clin Chim Acta. 1969 Feb;23(2):353-64 - PubMed
  10. Clin Chem. 1970 Aug;16(8):707-13 - PubMed
  11. Am J Med. 1964 Apr;36:561-70 - PubMed
  12. Cancer Res. 1969 Nov;29(11):1895-903 - PubMed
  13. Clin Sci. 1968 Oct;35(2):353-62 - PubMed
  14. J Clin Invest. 1961 Aug;40:1486-94 - PubMed
  15. J Lab Clin Med. 1969 Jun;73(6):909-16 - PubMed

Publication Types